Atomwise

Atomwise uses artificial intelligence to revolutionize drug discovery, applying its technology to the challenge of developing new medicines. By marrying the power of convolutional neural networks with vast chemical databases, Atomwise's machine learning-based discovery engine can identify new small molecule drugs.

Atomwise's approach works even for difficult, poorly classified targets by speeding up drug discovery so more potential treatments can be developed. Among its advantages:

• Ability to drug poorly categorized targets: No crystal structure or local ligand training data is required.
• Interrogation of vast chemical space: Computational speed means trillions of compounds can be screened in silico for better odds of success.
• Scalable discovery engine: A single global model is applied to all targets, and it can be rapidly scaled up and industrialized for the discovery process.
• Network effects drive model predictivity: Ongoing training data generation improves the global model's predictivity.

Atomwise's AI technology has been used to identify small molecule hits for more undruggable targets than any other AI drug discovery platform. The company's technology is designed to work at massive scale and speed, employing industry leading tools for AI and ML.

Atomwise has a broad pipeline of projects in different disease areas, including immunology, with targets like TYK2 and RIPK2. It's got partnerships with big pharmaceutical companies like Sanofi, GC Pharma and Bayer, as well as research partnerships with academic and nonprofit labs, with hundreds of projects to validate the technology.

The company doesn't reveal pricing details, but it offers a platform to transform drug discovery with the latest AI technology, a potentially useful tool for pharma companies, researchers and scientists. With AI, Atomwise hopes to make better drugs faster and more economically.

Published on August 10, 2024